APOGEE THERAPEUTICS INC (APGE) Stock Price, Forecast & Analysis
USA - NASDAQ:APGE - US03770N1019 - Common Stock
APGE Key Statistics, Chart & Performance
The current stock price of APGE is 56.25 USD. In the past month the price increased by 41.48%. In the past year, price increased by 2.84%.
APGE Latest News, Press Relases and Analysis
APGE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.67 | 386.64B | ||
| AMGN | AMGEN INC | 13.52 | 158.78B | ||
| GILD | GILEAD SCIENCES INC | 14.74 | 149.79B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.06 | 108.83B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.59 | 69.58B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 345.38 | 58.85B | ||
| ARGX | ARGENX SE - ADR | 61.47 | 50.15B | ||
| INSM | INSMED INC | N/A | 40.44B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.97 | 33.84B | ||
| NTRA | NATERA INC | N/A | 27.14B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.82B | ||
| BIIB | BIOGEN INC | 9.17 | 22.50B |
Related stock screener links
About APGE
Company Profile
Apogee Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 196 full-time employees. The company went IPO on 2023-07-14. The firm is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
Company Info
APOGEE THERAPEUTICS INC
221 Crescent St., Building 17, Suite 102B
Waltham MASSACHUSETTS US
Employees: 196
Phone: 16503945230
APOGEE THERAPEUTICS INC / APGE FAQ
What does APOGEE THERAPEUTICS INC do?
Apogee Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 196 full-time employees. The company went IPO on 2023-07-14. The firm is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
What is the current price of APGE stock?
The current stock price of APGE is 56.25 USD. The price increased by 0.37% in the last trading session.
What is the dividend status of APOGEE THERAPEUTICS INC?
APGE does not pay a dividend.
What is the ChartMill technical and fundamental rating of APGE stock?
APGE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is APOGEE THERAPEUTICS INC (APGE) stock traded?
APGE stock is listed on the Nasdaq exchange.
How many employees does APOGEE THERAPEUTICS INC have?
APOGEE THERAPEUTICS INC (APGE) currently has 196 employees.
APGE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to APGE. When comparing the yearly performance of all stocks, APGE is one of the better performing stocks in the market, outperforming 83.64% of all stocks.
APGE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to APGE. No worries on liquidiy or solvency for APGE as it has an excellent financial health rating, but there are worries on the profitability.
APGE Financial Highlights
Over the last trailing twelve months APGE reported a non-GAAP Earnings per Share(EPS) of -4.13. The EPS decreased by -99.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.13% | ||
| ROE | -38.37% | ||
| Debt/Equity | 0 |
APGE Forecast & Estimates
16 analysts have analysed APGE and the average price target is 95.54 USD. This implies a price increase of 69.85% is expected in the next year compared to the current price of 56.25.